Rakuten Medical is a clinical and commercial-stage biotech company advancing its investigational Alluminox™ platform, which is based on photoimmunotherapy. The company is developing the platform consisting of drug and device to treat cancers. Its lead asset, ASP-1929, an antibody-dye conjugate targeting EGFR, is currently in a global Phase 3 trial in combination with anti-PD-1 therapy for 1L recurrent head and neck cancer. ASP-1929 has already received marketing approval in Japan since 2021 for unresectable, locally advanced, or recurrent head and neck cancer. As of today, the company has completed over 1,000 commercial treatments in Japan.